Search
Menu
Home
HTB
2004
April
02
HTB
2 April 2004
Contents
Conference reports
Rosiglitazone shows no benefit for lipoatrophy
Hypertension related to HAART in HIV-positive women
Testosterone therapy for women with low androgen levels or body weight
Nevirapine, pregnancy and adverse events
Prior nevirapine exposure for pregnant women can contribute to treatment failure
Conflicting findings with HAART use in pregnancy and prematurity
Antiretrovirals, mode of delivery and transmission risk
Tenofovir studies in children
Increase of non-AIDS defining cancers in HOPS cohort
HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1
Epoetin-alfa improves interferon/ribavirin-associated anaemia
Antiretrovirals
Gilead discontinues DAPD development
Treatment access
International community meeting on drug pricing
Global Fund halts $92 million grant for Ukraine after problems
Global Fund says it needs $5 billion during 2004-2005
South African minister of health in line to chair Global Fund
Thai ddI patent case serves as example to other developing countries, Lancet viewpoint piece says
UK gives £3 million to WHO’s ‘3 by 5’ treatment goal
Hepatitis coinfection
International panel issues new guidelines for the care of HIV-HCV coinfected patients
NICE approves pegylated interferon plus ribavirin in UK
Other news
New HIV cases in England and Wales increase by 20% in past year
Micronutrient supplements may enhance survival; research has implications for poor countries
Durex withdraws N-9 condoms
On the web
Medical resources
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage